SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-022226
Filing Date
2023-02-15
Accepted
2023-02-15 08:13:31
Documents
4
Period of Report
2023-03-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm233330-2_def14a.htm DEF 14A 688648
2 GRAPHIC lg_outlooktherapeutics-4clr.jpg GRAPHIC 38405
3 GRAPHIC px_proxy1p1-bw.jpg GRAPHIC 1071351
4 GRAPHIC px_proxy1p2-bw.jpg GRAPHIC 588489
  Complete submission text file 0001104659-23-022226.txt   2802860
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 23633684
SIC: 2836 Biological Products, (No Diagnostic Substances)